Previous Article | Next Article ![]()
Clinical and Vaccine Immunology, April 2006, p. 507-510, Vol. 13, No. 4
1071-412X/06/$08.00+0 doi:10.1128/CVI.13.4.507-510.2006
Copyright © 2006, American Society for Microbiology. All Rights Reserved.
Vaccine Evaluation Unit, Health Protection Agency North West, P.O. Box 209, Clinical Sciences Building, Manchester Royal Infirmary, Manchester, United Kingdom,1 Department of Pathology and Microbiology, University of Bristol, Bristol, United Kingdom,2 Immunisation Department, HPA Centre for Infections, Collindale, London, United Kingdom,3 Gloucester Vaccine Evaluation Unit, Gloucester HPA, Gloucester, United Kingdom,4 Bristol HPA Laboratory, Bristol, United Kingdom5
Received 8 December 2005/ Returned for modification 9 December 2005/ Accepted 15 February 2006
Changes in the immunoglobulin G1 (IgG1)/IgG2 ratio following vaccination can indicate the activation of cellular control mechanisms typical of a T-cell-dependent response. We examined IgG subclass ratios in 17 healthy adults (26 to 55 years of age) before and 4 to 6 weeks following immunization with a quadrivalent meningococcal-polysaccharide diphtheria toxoid conjugate vaccine against serogroups A, C, Y, and W135. Serologic responses were determined by serum bactericidal antibody assay and serogroup-specific IgG, IgG1, and IgG2 enzyme-linked immunosorbent assay. Prevaccination serogroup A-specific IgG1/IgG2 ratios were <1 for all subjects and differed by subject for C, Y, and W-135. Postvaccination, significant increases in IgG, IgG1, and IgG2, were observed for all serogroups. Serogroup-specific IgG1/IgG2 ratios increased for group A (14/17 subjects, 88%), decreased in more than half of subjects for groups C (9/17, 53%) and W135 (12/17, 71%) and decreased for serogroup Y (16/17, 94%). IgG1/IgG2 ratios differed between individual vaccinees and were similar to the responses of adults who received pneumococcal conjugate vaccines or a monovalent C conjugate vaccine. Further studies on IgG subclasses following meningococcal polysaccharide and conjugate vaccination are needed.
This article has been cited by other articles:
| Antimicrob. Agents Chemother. | Clin. Microbiol. Rev. | Infect. Immun. |
|---|---|---|
| J. Clin. Microbiol. | J. Virol. | ALL ASM JOURNALS |